The two vaccines induce the immune system to target a critical protein on the surface of RSV ... the presence or absence of ...

COVID-19 (S Protein) is under clinical development by Vaxart and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

COVAX-19 is under clinical development by Vaxine and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Endothelial inflammation, as measured by E-selectin, was significantly associated with hypoxemia measures, even after adjusting for BMI.

Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing ...

The key protein for repairing nerve fibers has been "captured" Pfizer 2020 performance: Ibrance lost in adjuvant treatment of ...

F protein-subunit based vaccines, adjuvants & potency Both prefusion and postfusion F protein vaccines are being tested in clinical trials. Previous studies showed that alum had a modest effect on ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...